Abciximab i.v. Versus i.c. in Primary PCI Patients With STEMI
Randomized comparison of abciximab i.v. versus i.c. in patients with STEMI undergoing primary PCI. The hypothesis is, that higher concentration of abciximab i.c. leads to improved epicardial flow, perfusion, reduction of no-reflow, reduction in infarct size and subsequently better outcome.
Drug: Abciximab i.v.
Drug: Abciximab i.c.
|Study Design:||Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Single Blind
Primary Purpose: Treatment
|Official Title:||Randomized Comparison of Abciximab i.v. Versus i.c. in Primary PCI Patients With STEMI and Effects on Infarct Size and Microvascular Obstruction|
- Infarct size and microvascular obstruction assessed by MRI
- ST-segment resolution, TIMI-Flow, TIMI blush grade, ejection fraction, left ventricular volumes, clinical outcome (MACE)
|Study Start Date:||January 2006|
|Study Completion Date:||February 2008|
|Estimated Primary Completion Date:||November 2007 (Final data collection date for primary outcome measure)|
Please refer to this study by its ClinicalTrials.gov identifier: NCT00299377
|University of Leipzig - Heart Center|
|Leipzig, Germany, 04289|
|Principal Investigator:||Holger Thiele||University of Leipzig|